Highly Purified Eicosapentaenoic Acid Treatment Improves Nonalcoholic Steatohepatitis

Tanaka, Naoki; Sakai, Kenji; Horiuchi, Akira; Tanaka, Eiji; Kiyosawa, Kendo; Aoyama, Toshifumi

doi:10.1097/mcg.0b013e31815591aa

Cited by 215 publications

(173 citation statements)

References 37 publications

Supporting

Mentioning

160

Contrasting

Unclassified

Order By: Relevance

“…Their results indicated that n-3 PUFAs improved NAFLD characteristics such as ALT, AST, GGT, triglyceride and fasting glucose concentrations. Another clinical trial conducted in 23 patients with NASH found the same results [70] . A recent systematic review reported a beneficial effect of omega-3 supplementation on hepatic fat content and AST, although the effect size was relatively small [71] .…”

Section: Anti-inflammatory Agentssupporting

confidence: 66%

Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease

Eslamparast¹,

Eghtesad²,

Poustchi³

et al. 2014

WJH

View full text Add to dashboard Cite

Section: Anti-inflammatory Agentssupporting

confidence: 66%

Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease

Eslamparast¹,

Eghtesad²,

Poustchi³

et al. 2014

WJH

View full text Add to dashboard Cite

“…In 2 controlled studies (n = 40 and 144, respectively), omega-3 fatty acids combined with diet reduced transaminase levels and hepatic fatty infiltration in ultrasound more than diet alone in patients with NAFLD [57,58] . In the only study that assessed the effects of omega-3 fatty acids on liver histology, treatment with the omega-3 fatty acid eicosipentanoic acid (EPA) for 12 mo reduced transaminase levels in 23 patients with NASH [59] . An improvement in liver steatosis, ballooning, inflammation and fibrosis was observed in 6 out of 7 patients who underwent liver biopsy at the end of follow-up [59] .…”

Section: Omega-3 Fatty Acidsmentioning

confidence: 99%

“…In the only study that assessed the effects of omega-3 fatty acids on liver histology, treatment with the omega-3 fatty acid eicosipentanoic acid (EPA) for 12 mo reduced transaminase levels in 23 patients with NASH [59] . An improvement in liver steatosis, ballooning, inflammation and fibrosis was observed in 6 out of 7 patients who underwent liver biopsy at the end of follow-up [59] . The only study that evaluated the effects of high doses of omega-3 fatty acids on CVD events is the Japan EPA Lipid Intervention Study (JELIS), in which Japanese patients with hypercholesterolemia were randomly assigned to receive statin alone or statin combined with EPA 1800 mg/d [54] .…”

Section: Omega-3 Fatty Acidsmentioning

confidence: 99%

Lipid-lowering agents in the management of nonalcoholic fatty liver disease

Τζιόμαλος¹

2014

WJH

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in developed countries and is associated not only with increased risk for liver disease-related complications but also with higher cardiovascular morbidity. Accordingly, lipid-lowering agents are frequently considered in these patients to reduce cardiovascular risk. However, there have been concerns regarding the safety of these agents in patients with chronic liver diseases. In the present review, we discuss the safety of lipid-lowering agents in patients with NAFLD as well as their effects on both cardiovascular and liver disease in this population. Accumulating data suggest that statins are safe in patients with NAFLD and that they reduce the increased cardiovascular morbidity of this population. However, it is still unclear whether statins are also useful as a treatment for NAFLD per se , since there are very limited and conflicting data on their effects on liver histology. There is also very scarce evidence regarding the safety and efficacy of other lipid-lowering agents in patients with NAFLD. Randomized controlled studies are needed to evaluate the role of lipid-lowering agents and particularly statins for the prevention of both cardiovascular and liver disease-related complications in this high-risk population. Core tip: Accumulating data suggest that statins are safe in patients with nonalcoholic fatty liver disease (NAFLD) and that they reduce the increased cardiovascular morbidity of this population. However, it is still unclear whether statins are also useful as a treatment for NAFLD per se , since there are very limited and conflicting data on their effects on liver histology. There is also very scarce evidence regarding the safety and efficacy of other lipid-lowering agents in patients with NAFLD.Tziomalos K. Lipid-lowering agents in the management of nonalcoholic fatty liver disease.

show abstract

“…Patients were considered to have diabetes if they had a fasting glucose level equal to or higher than 126 mg/dl, or if they were taking insulin or oral hypoglycemic drugs. [8][9][10] …”

Section: Patientsmentioning

confidence: 99%

Efficacy and safety of addition of minor bloodletting (petit phlebotomy) in hepatitis C virus-infected patients receiving regular glycyrrhizin injections

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

Highly Purified Eicosapentaenoic Acid Treatment Improves Nonalcoholic Steatohepatitis

Cited by 215 publications

References 37 publications

Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease

Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease

Lipid-lowering agents in the management of nonalcoholic fatty liver disease

Efficacy and safety of addition of minor bloodletting (petit phlebotomy) in hepatitis C virus-infected patients receiving regular glycyrrhizin injections

Contact Info

Product

Resources

About